RQC Restoration Therapy for Neurodegeneration

RQC Restoration Therapy for Neurodegeneration

Overview

RQC Restoration Therapy for Neurodegeneration

Overview

Ribosome-associated Quality Control (RQC) is a conserved cellular machinery that resolves translational stalls on ribosomes, preventing the production of truncated, toxic protein fragments. Mutations in RQC components—including [Listerin (LTN1)](/entities/ltn1-gene), [Rqc2](/entities/rqc2-protein), and the C-terminal Domain (CTD) of [ZNF598](/entities/znf598-protein)—are directly linked to familial [amyotrophic lateral sclerosis (ALS)](/diseases/als-ftd-spectrum) and [frontotemporal dementia (FTD)](/diseases/frontotemporal-dementia). This therapy proposes enhancing RQC activity to clear stalled translation complexes, reduce toxic protein fragment burden, and restore proteostasis in neurodegenerative conditions.

Biological Background

The RQC Machinery

When a ribosome stalls during translation—due to mRNA damage, codon depletion, or problematic nascent chains—the RQC takes over:

RQC in Neurodegeneration

Genetic evidence directly implicates RQC dysfunction in neurodegeneration:

• Listerin (LTN1) mutations: Frameshift mutations near the C-terminus cause autosomal recessive ALS (MND/ALS type 6)
• Rqc2 (NEMF) variants: Associated with ALS-FTD spectrum disorders through impaired CAT-tailing
• ZNF598/GIGYF2: Variants linked to neurodevelopmental delay and Parkinson's disease
• RPL10/uL16: Mutations cause X-linked syndromic intellectual disability with motor phenotypes

Therapeutic Mechanisms

1. RQC Enhancer Small Molecules

Target: ZNF598-CTD allosteric modulators, Listerin RING domain activators

Approach:

• Screen for small molecules that increase ZNF598 autophosphorylation or Listerin ubiquitination activity
• Target RQC with compounds that promote ribosomal collision resolution
• Enhance Ltn1-RING activity to increase ubiquitination flux through the pathway

2. Rqc2/CAT-Tailing Modulation

Target: Rqc2 ([NEMF](/entities/nemf-protein)) interaction interfaces

Approach:

• Stabilize Rqc2-60S interaction to ensure complete CAT-tailing
• Prevent Rqc2 aggregation by small molecules or targeted protein degradation
• Promote productive extraction of CAT-tailed proteins

3. Ribosomal Collision Resolution Enhancement

Target: [HBS1L](/entities/hbs1l-protein)-[ABCE1](/entities/abce1-protein) splitting complex

Approach:

• Increase HBS1L GTPase activity to accelerate ribosome release
• Enhance ABCE1 ATPase activity for efficient ribosome splitting
• Promote Dom34/Hbs1 recruitment to stalled complexes

4. Gene Therapy for RQC Component Overexpression

Target: [Listerin (LTN1)](/entities/ltn1-gene), [Rqc2 (NEMF)](/entities/nemf-protein), [ZNF598](/entities/znf598-protein)

Approach:

• AAV-mediated overexpression of wild-type Listerin in motor neurons and cortical neurons
• Viral delivery of ZNF598 to restore collision-sensing capacity
• CRISPR activation (CRISPRa) of endogenous RQC genes

Disease Relevance

ALS/FTD (Primary Indication)

• Direct genetic validation: Listerin (LTN1) recessive mutations cause ALS
• Impaired CAT-tailing in NEMF variant carriers
• RQC overload from C9orf72 DPR toxicity creates dependency on RQC machinery
• Score contribution: 10/10 for ALS, 10/10 for FTD

Alzheimer's Disease

• Ribosomal stalling increases in AD brain (tau phosphorylation affects translation)
• RQC dysfunction could contribute to Aβ and tau fragment accumulation
• Amyloid precursor protein ([APP](/genes/app)) contains rare codons that naturally stall ribosomes
• Score contribution: 7/10 for AD

Parkinson's Disease

• α-synuclein ([SNCA](/genes/snca)) mRNA contains secondary structures that slow translation
• Translation stalling increases oxidative stress and protein aggregation
• RQC overload from α-syn overexpression may create vulnerability
• Score contribution: 7/10 for PD

Aging

• RQC efficiency declines with age (proteostasis network decline)
• Accumulation of truncated proteins is a hallmark of aged neurons
• Score contribution: 8/10 for aging

10-Dimension Rubric Scoring

| Dimension | Score (0-10) | Rationale |
|-----------|:---:|---|
| Novelty | 9 | Direct RQC targeting for neurodegeneration is essentially unexplored clinically |
| Mechanistic Rationale | 8 | Strong genetic evidence (LTN1, NEMF, ZNF598); clear biochemical mechanism |
| Root-Cause Coverage | 8 | Addresses proteostasis at the translational level, upstream of aggregation |
| Delivery Feasibility | 5 | Gene therapy (AAV) for motor neurons is established (Spinraza, etc.); small molecules harder to design |
| Safety Plausibility | 7 | RQC is essential but not rate-limiting; partial enhancement likely safe |
| Combinability | 8 | Synergizes with proteasome enhancers, autophagy inducers, and protein synthesis inhibitors |
| Biomarker Availability | 6 | CAT-tailed protein fragments in CSF as candidate biomarker; not yet clinically validated |
| De-risking Path | 7 | Drosophila models available; primary neurons from patient iPSCs accessible |
| Multi-disease Potential | 8 | ALS/FTD primary, AD/PD secondary, aging universal |
| Patient Impact | 7 | ALS/FTD patients have highest unmet need; disease-modifying potential |

Total Score: 73/100

Implementation Roadmap

Phase 1: Target Validation (12 months, $2-3M)

• M1: Validate RQC component expression in post-mortem ALS, AD, PD brain tissue (RNAscope, western blot)
• M2: iPSC-derived motor neurons from LTN1/NEMF mutation carriers: measure CAT-tailed proteins, truncated protein accumulation
• M3: Develop AlphaLISA or SIMOA assay for CAT-tailed protein fragments in human CSF
• M4: DrosophilaALS model (LTN1 knockdown) to confirm truncated protein toxicity and rescue by RQC enhancement

Phase 2: Small Molecule and Gene Therapy Development (24 months, $8-12M)

• M1: High-throughput screen for Listerin RING domain activators (FRET-based ubiquitination assay)
• M2: Develop AAV9-LTN1 construct for CNS delivery (validates against Spinraza's precedent)
• M3: Off-target profiling of hit compounds
• M4: Dose-response studies in primary neurons and human iPSC-derived motor neurons

Phase 3: IND-Enabling Studies (18 months, $10-15M)

• M1: GLP toxicology (AAV9-LTN1: NHP studies)
• M2: GMP manufacturing for lead compound or gene therapy
• M3: IND submission

Key Risks and Mitigation

| Risk | Likelihood | Impact | Mitigation |
|------|:---:|:---:|---|
| RQC enhancers cause off-target translation inhibition | Medium | High | Wide therapeutic window expected; titrate carefully |
| AAV9 delivery insufficient for cortical neurons | Medium | High | Use novel capsids (AAV-PHP.eB, AAV-F travasculature) |
| CAT-tailing enhancement produces new toxic species | Low | High | Monitor in Phase 1-2 assays |
| Limited commercial incentive (small patient population) | Medium | Medium | Pursue orphan designation; combination with larger indications |

Actionable Next Steps

Lab Experiments

Clinical Protocol Design

Company Partnership Opportunities

• uniQure (AAV gene therapy for neurodegenerative diseases)
• Denali Therapeutics (precision medicine approach for neurodegenerative diseases)
• Roche/Genentech (neuroscience pipeline, ALS/FTD focus)

Grant Opportunities

• ALS Association Therapeutic Idea Award
• NINDS R01: Gene therapy for rare forms of ALS
• The Wellcome Trust: Translation of RQC modulators

Cross-Linking

• [Listerin (LTN1) gene](/entities/ltn1-gene) — primary target gene
• [Rqc2 (NEMF) protein](/entities/nemf-protein) — RQC component
• [ZNF598 protein](/entities/znf598-protein) — collision sensor
• [Proteostasis pathways](/mechanisms/proteostasis-network) — broader context
• [ALS-FTD spectrum disease](/diseases/als-ftd-spectrum) — primary disease indication
• [Protein synthesis and translation quality control](/mechanisms/protein-synthesis-quality-control) — mechanistic context